ISPOR ANNOUNCES CANDIDATES FOR 2016–2017 BOARD OF DIRECTORS

Published Feb 29, 2016
Princeton, NJ—February 29, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its candidates today for open positions on the 2016–2017 Board of Directors. The Board of Directors drives ISPOR's strategic direction and is responsible for the management of the Society, including its committees, publications, budget and governance. The Board is the policy making body of the Society.  The positions and candidates for the 2016–2017 ISPOR Board of Directors include: President-Elect - Newell McElwee, PharmD, MSPH Associate Vice President, Merck (North Wales, PA, USA) - Shelby D. Reed, PhD, RPh Professor, Duke University (Durham, NC, USA) Director - Mirjana Huic, MD, MSc, PhD Assistant Director, Croatia Agency for Quality and Accreditation in Health Care and Social Work (Zagreb, Croatia) - Joanna Lis, PhD, MSc, MBA Director of Market Access, Sanofi-Aventis (Warsaw, Poland) Director - Brian Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences (Irvine, CA, USA) - John Watkins, PharmD, MPH Formulary Manager, Premera Blue Cross (Mountlake Terrace, WA, USA) Director - Nathorn Chaiyakunapruk, PharmD, PhD Professor, School of Pharmacy, Monash University (Selangor, Malaysia) - Gordon Liu, PhD Professor of Economics, Peking University, National School of Development (Bejing, China) Director - Rosanna Tarricone, PhD, MSc Associate Professor, Bocconi University (Milan, Italy) - Mondher Toumi, MD, MSc, PhD Professor, University Aix-Marseille (Paris, France) ISPOR members will be invited to vote beginning March 1 with elections closing on May 1, 2016. Information on each of the candidates–including biographies and vision statements–can be found on the ISPOR Board of Directors Elections webpage. Only ISPOR global members are eligible to vote in the elections. Information about the Society and the benefits of membership can be found here.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×